Radiation Therapy Sandwiched Between Paclitaxel and Carboplatin in Patients With High-risk Endometrial Cancer

Inclusion Criteria:

• Histologically-documented high-risk endometrioid adenocarcinoma with no visible residual disease, defined by the following criteria:

  1. Surgical stage I disease with < 50 myometrial invasion and grade 3 tumor (IBG3) with lymphovascular space involvement;
  2. Surgical stage I disease with > 50% myometrial invasion and grade 2 or 3 tumor (ICG2, ICG3);
  3. Any surgical stage II disease (IIA, IIB);
  4. Any surgical stage III disease (IIIA, IIIB, IIIC); and
  5. Any surgical stage IV disease with no residual macroscopic tumor
• Surgical staging to include total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings, and lymph node samplings as per standard GOG criteria.
• Age > 18 years.
• ECOG performance status of < 2.

Exclusion Criteria:

• Patient has impairment of hepatic, renal or hematologic function as defined by the following baseline laboratory values:

  1. Serum SGOT and /or SGPT > 2.5 times the institutional upper limit of normal
  2. Total serum bilirubin > 1.5 mg/dl
  3. History of chronic or active hepatitis
  4. Serum creatinine > 2.0 mg/dl
  5. Platelets < 100,000/mm3
  6. Absolute neutrophil count (ANC) < 1500/mm3
  7. Hemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry).
• Patient has severe or uncontrolled concurrent medical disease (eg Un-controlled diabetes, unstable angina, myocardial infarction within 6 months, congestive heart failure, etc.)
• Patient with any prior chemotherapy or radiotherapy for pelvic malignancy.
• Patients with dementia or altered mental status that would prohibit the giving and understanding of informed consent at the time of study entry.
• Patients with any history of cancer with the exception of non-melanoma skin cancer are excluded if there is any evidence of other malignancy being present within the past five years.